Back to Browse Journals » OncoTargets and Therapy » Volume 3

Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine

Authors Steven E McCormack, Erica D Warlick

Published 22 July 2010 Volume 2010:3 Pages 157—165


Review by Single-blind

Peer reviewer comments 4

Steven E McCormack, Erica D Warlick

Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA

Abstract: Myelodysplastic syndromes (MDS) are a varied group of diseases leading to ­significant morbidity and mortality. Therapy of MDS has been difficult, with supportive cares used to ameliorate symptoms, and hematopoietic stem cell transplantation the only curative option. Agents, such as the cytidine analog azacitidine, exert an effect on DNA methyltransferase leading to a reduction in DNA methylation, a process thought to be key to the pathogenesis of MDS. Recently, azacitidine has been shown to prolong survival and improve quality of life in patients with MDS, while maintaining a favorable adverse effect profile. This review highlights the scientific rationale for the use of azacitidine in addition to its application in current clinical practice for patients with MDS.

Keywords: hypomethylation, epigenetics, myelodysplastic syndromes, azacitidine

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Synthesis, pharmacokinetics, and biological use of lysine-modified single-walled carbon nanotubes

Mulvey JJ, Feinberg EN, Alidori S, McDevitt MR, Heller DA, Scheinberg DA

International Journal of Nanomedicine 2014, 9:4245-4255

Published Date: 4 September 2014

Choroidal and macular thickness changes induced by cataract surgery

Falcão MS, Gonçalves NM, Freitas-Costa P, Beato JB, Rocha-Sousa A, Carneiro Â, Brandão EM, Falcão-Reis FM

Clinical Ophthalmology 2014, 8:55-60

Published Date: 16 December 2013

Zirconium, calcium, and strontium contents in magnesium based biodegradable alloys modulate the efficiency of implant-induced osseointegration

Mushahary D, Sravanthi R, Li Y, Kumar MJ, Harishankar N, Hodgson PD, Wen C, Pande G

International Journal of Nanomedicine 2013, 8:2887-2902

Published Date: 9 August 2013

The safety and efficacy of aspirin intake in photoselective vaporization laser treatment of benign prostate hyperplasia

Shao IH, Hou CP, Chen SM, Chen CL, Lin YH, Chang PL, Tsui KH

Clinical Interventions in Aging 2013, 8:431-432

Published Date: 16 April 2013

Vesiculation of biological membrane driven by curvature induced frustrations in membrane orientational ordering

Jesenek D, Perutková S, Góźdź W, Kralj-Iglič V, Iglič A, Kralj S

International Journal of Nanomedicine 2013, 8:677-687

Published Date: 19 February 2013

Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia

Hoeksema KA, Jayanthan A, Cooper T, Gore L, Trippett T, Boklan J, Arceci RJ, Narendran A

OncoTargets and Therapy 2011, 4:149-168

Published Date: 5 September 2011

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes

Jacqueline S Garcia, Nitin Jain, Lucy A Godley

OncoTargets and Therapy 2010, 3:1-13

Published Date: 25 February 2010

Fludarabine in the treatment of chronic lymphocytic leukemia: a review

Francesca Ricci, Alessandra Tedeschi, Enrica Morra, Marco Montillo

Therapeutics and Clinical Risk Management 2009, 5:187-207

Published Date: 4 March 2009

Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2

Allen J Taylor, Daming Zhu, Lance E Sullenberger, Hyun J Lee, Jeannie K Lee, Karen A Grace

Vascular Health and Risk Management 2007, 3:159-164

Published Date: 15 March 2007